



IFW

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

MKRAWZSENEK@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3020

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598


February 25, 2005

CERTIFICATE OF MAILING 37 C.F.R 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

February 25, 2005

Date


Michael R. Krawzsenek

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/693,657 entitled "CYTOKINE RECEPTOR MODULATORS, METHOD OF IDENTIFYING SAME, AND METHOD OF MODULATING CYTOKINE RECEPTORS ACTIVITY WITH SAME" – Sylvain Chemtob et al.*
Our reference: GOUD:040US
Client reference: CG/12810.81

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, replacement Form PTO-1449, supplemental Form PTO-1449, and reference B1.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:040US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Michael R. Krawzsenek
Reg. No. 51,898

MRK/kvp
Encl.: as noted

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Sylvain Chemtob *et al.*

Serial No.: 10/693,657

Filed: October 24, 2003

For: CYTOKINE RECEPTOR MODULATORS,
METHOD OF IDENTIFYING SAME,
AND METHOD OF MODULATING
CYTOKINE RECEPTORS ACTIVITY
WITH SAME



Group Art Unit: 1644

Examiner: Unknown

Atty. Dkt. No.: GOUD:040US

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

February 25, 2005

Date


Michael R. Krawzsehek

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of references not previously cited on November 16, 2004 and copies of cited U.S. patents, U. S. patent application publications and co-pending U.S. patent applications subject to the waiver regarding the requirement under 37 C.F.R. §1.98(a)(2)(i) stated in the Official Gazette Notice dated August 5, 2003 regarding patent applications filed on or after June 30, 2003 have not been

enclosed. Due to the typographical errors contained in the Form PTO-1449 previously filed on November 16, 2004, applicants request that the concurrently filed Form PTO-1449 replace the previously filed Form PTO-1449. In addition, applicants have supplied a supplemental Form-1449 with two additional references to be considered.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:040US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Michael R. Krawzsenek
Reg. No. 51,898
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 25, 2005

Form PTO-1449 (modified)

List of Patents and Publications for Applicant

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

GOUD:040US

Serial No.

10/693,657

Applicant

Sylvain Chemtob *et al.*

Filing Date:

October 24, 2003

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Baker <i>et al.</i> , "Cell proliferation kinetics of normal and tumour tissue in vitro: quiescent reproductive cells and the cycling reproductive fraction," <i>Cell Prolif.</i> , 28(1):1-15, 1995.
	C2	Brady and Dodson, "Reflections on a peptide," <i>Nature</i> , 368:692-693, 1994.
	C3	Carell <i>et al.</i> , "A novel procedure for the synthesis of libraries containing small organic molecules," <i>Angew Chem Int Ed Engl</i> , 33(20):2059-2061, 1994.
	C4	Chevion <i>et al.</i> , "The antiproliferative activity of the tetra peptide acetyl-N-SerAspLysPro, an inhibitor of hematopoietic stem cell proliferation, is not mediated by a thymosin β 4-like effect on actin assembly," <i>Cell Prolif.</i> , 29(8):437-446, 1996.
	C5	Cho <i>et al.</i> , "An unnatural biopolymer," <i>Science</i> , 261:1303-1305, 1993.
	C6	Coller <i>et al.</i> , "Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation," <i>J. Biol. Chem.</i> , 268:20741-20743, 1993.
	C7	Cull <i>et al.</i> , "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor," <i>Proc. Natl. Acad. Sci., USA</i> , 89:1865-1869, 1992.
	C8	DeWitt <i>et al.</i> , "'Diversomers': an approach to nonpeptide, nonoligomeric chemical diversity," <i>Proc. Natl. Acad. Sci., USA</i> , 90:6909-6913, 1993.
	C9	Elliot <i>et al.</i> , "Bin1 functionally interacts with myc and inhibits cell proliferation via multiple mechanisms," <i>Oncogene</i> , 18(24):3564-3573, 1999.

25359089.1

EXAMINER:

DATE CONSIDERED:


EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

List of Patents and Publications Received by Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

GOUD:040US

Serial No.

10/693,657

Applicant

Sylvain Chemtob *et al.*

Filing Date:

October 24, 2003

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Erb <i>et al.</i> , "Recursive deconvolution of combinatorial chemical libraries," <i>Proc. Natl. Acad. Sci., USA</i> , 91:11422-11426, 1994.
	C11	Fodor <i>et al.</i> , "Multiplexed biochemical assays with biological chips," <i>Nature</i> , 364:555-556, 1993.
	C12	Gallop <i>et al.</i> , "Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries," <i>Journal of Medicinal Chemistry</i> , 37(9):1233-1251, 1994.
	C13	Houghten <i>et al.</i> , "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," <i>BioTechniques</i> , 13(3):412-421, 1992.
	C14	Hu <i>et al.</i> , " α_1 -adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase ¹ ," <i>J. Pharmacol. Exp. Ther.</i> , 290(1):28-37, 1999.
	C15	Jameson <i>et al.</i> , "A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis," <i>Nature</i> , 368:744-746, 1994.
	C16	Lam <i>et al.</i> , "A new type of synthetic peptide library for identifying ligand-binding activity," <i>Nature</i> , 354:744-746, 1991.
	C17	Lam, "Application of combinatorial library methods in cancer research and drug discovery," <i>Anti-Cancer Drug Design</i> , 12:145-167, 1997.
	C18	Merrifield, "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," <i>J. Am. Chem. Soc.</i> , 85:2149-2154, 1964.
	C19	Piossek <i>et al.</i> , "Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF," <i>The Journal of Biological Chemistry</i> , 274(9):5612-5619, 1999.
	C20	Powell <i>et al.</i> , "Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum," <i>Pharmaceutical Res.</i> , 10(9):1268-1273, 1993.
	C21	Scott and Smith, "Searching for peptide ligands with an epitope library," <i>Science</i> , 249:386-390, 1990.
	C22	Tamaskovic <i>et al.</i> , "Enzyme-linked immunosorbent assay for the measurement of JNK activity in cell extracts," <i>Biol. Chem.</i> , 380:569-578, 1999.

25359089.1

EXAMINER:

DATE CONSIDERED:


EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

List of Patents and Publications for Applicant

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

GOUD:040US

Serial No.

10/693,657

Applicant

Sylvain Chemtob *et al.*

Filing Date:

October 24, 2003

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Erb <i>et al.</i> , "Recursive deconvolution of combinatorial chemical libraries," <i>Proc. Natl. Acad. Sci., USA</i> , 91:11422-11426, 1994.
	C11	Fodor <i>et al.</i> , "Multiplexed biochemical assays with biological chips," <i>Nature</i> , 364:555-556, 1993.
	C12	Gallop <i>et al.</i> , "Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries," <i>Journal of Medicinal Chemistry</i> , 37(9):1233-1251, 1994.
	C13	Houghten <i>et al.</i> , "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," <i>BioTechniques</i> , 13(3):412-421, 1992.
	C14	Hu <i>et al.</i> , " α_1 -adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase ¹ ," <i>J. Pharmacol. Exp. Ther.</i> , 290(1):28-37, 1999.
	C15	Jameson <i>et al.</i> , "A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis," <i>Nature</i> , 368:744-746, 1994.
	C16	Lam <i>et al.</i> , "A new type of synthetic peptide library for identifying ligand-binding activity," <i>Nature</i> , 354:744-746, 1991.
	C17	Lam, "Application of combinatorial library methods in cancer research and drug discovery," <i>Anti-Cancer Drug Design</i> , 12:145-167, 1997.
	C18	Merrifield, "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," <i>J. Am. Chem. Soc.</i> , 85:2149-2154, 1964.
	C19	Piossek <i>et al.</i> , "Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF," <i>The Journal of Biological Chemistry</i> , 274(9):5612-5619, 1999.
	C20	Powell <i>et al.</i> , "Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum," <i>Pharmaceutical Res.</i> , 10(9):1268-1273, 1993.
	C21	Scott and Smith, "Searching for peptide ligands with an epitope library," <i>Science</i> , 249:386-390, 1990.
	C22	Tamaskovic <i>et al.</i> , "Enzyme-linked immunosorbent assay for the measurement of JNK activity in cell extracts," <i>Biol. Chem.</i> , 380:569-578, 1999.

25359089.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. GOUD:040US	Serial No. 10/693,657
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Sylvain Chemtob <i>et al.</i>	
		Filing Date: October 24, 2003	Group: 1644
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,223,409	6/29/93	Ladner <i>et al.</i>	435	69.7	3/01/91

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 93/14781	8/05/93	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25507417.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.